Local biotech Aardvark Therapeutics made its debut on the public market this month, making it San Diego’s first life science ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

It means the IPO should bring in gross proceeds of $ ... day option to buy a further 883,200 shares at the same price. The biotech’s pipeline is headed up by ARD-101, a bitter taste receptor ...

This was the fourth biotech IPO of 2025, and the company raised around $219 million in its IPO, intended to advance its cystic fibrosis treatments. That is a market dominated Vertex ...

Biotech stocks may be primed for a long-term bull run. Learn why IBB, XBI, and macro trends like rate cuts make biotech an ...

The worst of this storm may be over, as the 24 biotech IPOs conducted last year are a tick up from 2022 and 2023. Even so, the road to the public markets remains exceptionally fraught and energy ...

The biotech is developing two candidates ... Another slice of the targeted IPO haul is earmarked for a proof-of-concept trial of F598, Alopexx’s other lead candidate. Sanofi licensed the ...

The companies Eikon Therapeutics, Sionna Therapeutics, and Abcuro bagged the biggest biotech funding rounds overall in ...

The funding can support investment in as many as 60 new life sciences companies, said Sofinnova chairman Antoine Papiernik.

This week, Germany-based Anbio Biotechnology (NNNN) is expected to raise capital during its IPO. "NNNN is seeking US public capital market investment as it aims to commercialize its in vitro ...

Belrise Industries aims to raise Rs 2,150 crore, while Paramesu Biotech plans to mop up Rs 600 crore through the public issue ...